Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Several other research firms also recently issued reports on AMPH. Wells Fargo & Company reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 price objective on shares of Amphastar Pharmaceuticals in a report on Monday, July 31st. Piper Jaffray Companies set a $20.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, July 29th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Finally, TheStreet raised shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $19.86.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded up 2.79% during mid-day trading on Tuesday, reaching $15.49. 318,939 shares of the company’s stock were exchanged. The company’s 50 day moving average is $16.78 and its 200 day moving average is $15.88. The stock has a market capitalization of $715.56 million, a PE ratio of 201.17 and a beta of 1.65. Amphastar Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.05. The firm had revenue of $65.20 million for the quarter, compared to the consensus estimate of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 earnings per share. Equities research analysts anticipate that Amphastar Pharmaceuticals will post $0.27 EPS for the current fiscal year.

Amphastar Pharmaceuticals announced that its Board of Directors has approved a share buyback plan on Wednesday, August 9th that allows the company to repurchase $20.00 million in shares. This repurchase authorization allows the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/22/amphastar-pharmaceuticals-inc-amph-lowered-to-sell-at-valuengine.html.

In other news, Director Richard K. Prins sold 5,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $14.80, for a total value of $74,000.00. Following the completion of the sale, the director now directly owns 33,844 shares in the company, valued at $500,891.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael A. Zasloff sold 15,000 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $17.01, for a total transaction of $255,150.00. Following the completion of the sale, the director now owns 47,411 shares of the company’s stock, valued at $806,461.11. The disclosure for this sale can be found here. Insiders sold 51,482 shares of company stock valued at $842,225 over the last quarter. Company insiders own 11.10% of the company’s stock.

Several large investors have recently modified their holdings of AMPH. Victory Capital Management Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock worth $100,000 after buying an additional 842 shares during the period. Acrospire Investment Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock worth $109,000 after buying an additional 2,479 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $111,000. Envestnet Asset Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals during the first quarter worth approximately $115,000. Finally, Municipal Employees Retirement System of Michigan boosted its stake in shares of Amphastar Pharmaceuticals by 3.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 8,200 shares of the company’s stock worth $119,000 after buying an additional 290 shares during the period. Institutional investors and hedge funds own 43.83% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.